Treatment of palmoplantar psoriasis with intramuscular alefacept - 21/08/11
New Brunswick, New Jersey
Abstract |
Alefacept is a dimeric fusion protein that consists of the extracellular CD2–binding portion of human lymphocyte function–associated antigen-3, which is linked to the Fc segment of human IgG1.1 Alefacept inhibits T-cell activation and proliferation, and induces apoptosis of memory-effector (CD45RO+) T cells in vitro,2 limiting the inflammatory and uncontrolled keratinocyte proliferation seen in psoriatic lesions. Alefacept is the first biologic approved in the United States for the treatment of moderate to severe chronic plaque psoriasis. This report describes the use of alefacept in 2 patients with extensive and recalcitrant palmoplantar psoriasis who achieved significant improvements on alefacept therapy.
Le texte complet de cet article est disponible en PDF.Plan
Supported by Stiefel Laboratories. Funding sources: None. Disclosure: Dr Gottlieb is a consultant, speaker, and investigator for Biogen Idec, Inc, and for Amgen/Wyeth; and a consultant and investigator for Genentech and Centocor. She is an investigator for Abbott. These are the other companies developing biologics for psoriasis. |
Vol 53 - N° 2S
P. S127-S129 - août 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?